OEOya Ercan

Oya Ercan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Oya Ercan has a total of 305 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Near-final height outcomes in children with idiopathic short stature responsive to the IGF-1 generation test: a multicenter retrospective study of rhGH therapy

    by Yavuz Özer, Hatice Ilgın Ruhi, Hande Turan, Melikşah Keskin, Sezgin Şahin, Veysel Nijat Baş, Zeynep Şıklar, Firdevs Baş, Zehra Aycan, Merih Berberoğlu, et al.

    Children with idiopathic short stature (ISS) have reduced height potential without identifiable endocrine or systemic causes. Selecting appropriate candidates for recombinant human growth hormone (rhGH) therapy remains challenging. The aim of this study was to describe near-final height (NFH) outcomes and to identify clinical predictors of growth response in children with ISS who were selected for rhGH therapy based on a positive IGF-1 generation test (IGFGT). In this multicenter retrospective study (2009-2018) across four centers in Türkiye, patients diagnosed with ISS, baseline IGF-1 < 0 SDS, and ≥ 20% IGF-1 increment after IGFGT were included. GH1 gene sequencing was performed to exclude biologically inactive GH, a condition marked by normal or elevated GH secretion but impaired biological activity. NFH was defined as bone age ≥ 14 years in girls and ≥ 16 years in boys. Height SDS gain from baseline to NFH was evaluated. Sixty-three patients (28 females, 19 pubertal) were enrolled, of whom 55 had NFH data and were included in the final analysis. Mean age at treatment initiation was 10.8 ± 3.0 years. No GH1 mutations were identified. Among 55 patients with NFH data, mean height SDS increased from - 2.90 ± 0.77 at baseline to -1.92 ± 0.90 at NFH (p < 0.001), with a mean height SDS gain of 0.93 ± 0.68. The median difference between NFH SDS and baseline predicted adult height (PAH) SDS was - 0.06 (- 0.32-0.07). Predictors of NFH gain included female gender, target height (TH) SDS, baseline height-TH difference, baseline height-PAH difference, and first-year growth velocity SDS. rhGH therapy was associated with improvements in height SDS and NFH in this selected cohort of children with ISS. However, the absence of an untreated control group and the minimal difference between NFH and baseline PAH indicate that these findings should be interpreted with caution. Although no GH1 mutations were identified, the relatively high rate of parental consanguinity suggests that other genetic factors within the GH-IGF-1 axis or epiphyseal growth plate pathways may underlie the etiology of short stature. Not applicable.

  • Long-term endocrine and testicular outcomes in male survivors of childhood acute lymphoblastic leukemia

    by Hasan Karakaş, Gürkan Tarçın, Elvan Bayramoğlu, Hande Turan, Suheyla Ocak, Olcay Evliyaoğlu, Tiraje Celkan, Hilmi Apak, Oya Ercan


  • Test-Retest Reliability and Concurrent Validity of the One-Minute Sit to Stand Test in Children and Adolescents Who are Overweight or Obese

    by Nesrine Benkhalifa, Cigdem Emirza Cilbir, Oya Ercan, Goksen Kuran Aslan

    To assess test-retest reliability and concurrent validity of the 1-min sit-to-stand test (1-minSTST) in children and adolescents who are overweight or obese. Thirty-nine overweight and obese children and adolescents were included. The 1-minSTST was administered twice with a one-hour break. Concurrent validity was evaluated by assessing correlations between 1-minSTST repetitions and six-minute walk test (6MWT) distances. The cardiorespiratory measures (blood pressure, heart rate, oxygen saturation, respiratory rate, dyspnea, and perceived fatigue) were recorded before and after each test. Test-retest reliability was excellent (ICC: 0.90, 95% confidence interval 0.90-0.97). There was no relationship between scores on the 1-minSTST and 6MWT (r = -0.06, p = 0.71). No statistically significant correlation was found between scores on each test and change in cardiorespiratory responses, except for respiratory rate (r = 0.43, p = 0.006). Change in cardiorespiratory responses was similar when performing each test (p > 0.05). While the 1-minSTST seems promising, it is not significantly related to the 6MWT, indicating they may assess different dimensions of fitness in this population. Further investigations are needed to determine the clinical implications of 1-minSTST outcomes in pediatric population.

  • Open Access

    Midline brain abnormalities and associated endocrine dysfunctions: a clinical and MRI-based study

    by Yavuz Özer, Hande Turan, Gürkan Tarçın, Dilek Bingöl Aydın, Büşra Demirtaş, Olcay Evliyaoğlu, Sema Saltık, Oya Ercan

    Background: This study aimed to assess the spectrum and prevalence of endocrine disorders in pediatric patients with midline brain abnormalities (MBA). Methods: This retrospective observational study was conducted at a tertiary pediatric endocrinology center and included patients younger than 18 years of age with MBA. Clinical data were obtained from medical records. Results: The study included 17 patients (52.9% male) with a median age of 11.1 (8.9–15.7) years. The median age at first admission was 5.3 (1.5–9.9) years, and the median follow-up period was 6.8 (2.1–7.9) years. The most common clinical finding at admission was short stature (29.5%). Brain magnetic resonance imaging most frequently revealed corpus callosum abnormalities (52.9%), followed by septo-optic dysplasia (17.6%). Endocrine disorders were present in 82.3% of patients with MBA. The most frequently observed endocrine disorder was multiple pituitary hormone deficiency (41.2%). In addition, isolated endocrine disorders such as central hypothyroidism (17.6%), growth hormone deficiency (11.8%), diabetes insipidus (5.9%), and hypogonadotropic hypogonadism (5.9%) were observed. When each endocrine disorder was evaluated individually, central hypothyroidism emerged as the most frequently identified condition (58.8%). Three patients had no detectable endocrine dysfunction. Conclusions: Endocrine disorders were observed in 82.3% of patients with MBA, with central hypothyroidism being the most common when considered individually. The high prevalence of endocrine disorders in children with MBA underscores the importance of routine endocrine screening in this population.

  • Central precocious puberty in boys; diagnosis, treatment and follow-up: a nation-wide study

    by Sevinc Odabasi Gunes, Merve Sakar, Nursel Muratoglu Sahin, Gulay Karaguzel, Emine Ayca Cimbek, Feyza Darendeliler, Ezgi Sarban, Esra Doger, Ganimet Oner, Zeynep Siklar, et al.

    To evaluate demographic characteristics, clinical, laboratory, imaging features, and treatment responses of boys who were diagnosed and treated for central precocious puberty (CPP). The data were collected from pediatric endocrinology clinics in Türkiye. Patients were classified into two groups based on magnetic resonance imaging (MRI) findings, idiopathic CPP (iCPP) and organic CPP (oCPP). The oCPP group was further cathegorized into three subgroups: oCPP-confirmed, oCPP-unrelated, and oCPP-uncertain lesions. Among 232 patients, 62.9% were diagnosed with iCPP. All patients aged <3 years had oCPP-confirmed lesions. Basal luteinizing hormone (LH) and total testosterone (T) levels were higher in oCPP group than in iCPP group (p = 0.004 and p = 0.02, respectively). Basal LH, basal follicle-stimulating hormone (FSH), T, and peak LH/FSH were lower in the iCPP-obese group (p < 0.05). T differed significantly among the oCPP-confirmed, oCPP-unrelated, and oCPP-uncertain subgroups (p = 0.032). Among patients that reached final height (FH), the difference between target height (TH) standard deviation score (SDS) and FH SDS was higher in oCPP group than in iCPP group (p < 0.05). A positive correlation was found between predicted adult height at the treatment initiation and FH (r = 0.463 p = 0.020). Factors affecting FH were height SDS at the beginning of treatment, paternal height SDS, and TH SDS. The prevelance of oCPP was found lower compared with previous literature data. Currently, there is no reliable marker to predict oCPP that would allow clinicians to safely omit MRI in iCPP cases. However, boys under 3 years of age should be carefully evaluated for potential organic causes of CPP.


  • Open Access

    Validity of Different Anthropometric Indices in the Assessment of Body Composition of Children and Adolescents with Type 1 Diabetes

    by Yavuz Ozer, Didem Gunes Kaya, Emine Ulgen, Mehmet Enes Gokler, Oya Ercan

    Background: The prevalence of overweight and obesity in young people with type 1 diabetes (T1D) has been increasing despite current advancements in the management of T1D. Objectives: This study aimed to assess the prevalence of overweight/obesity using bioelectrical impedance analysis (BIA) in children and adolescents with T1D and evaluate the validity of new anthropometric indices, which have been recommended for defining overweight and obesity. Methods: A cross-sectional study was performed on subjects with T1D between the ages of 5 and 21 years. The patients' anthropometric measurements were obtained, and Body Mass Index (BMI), waist/height ratio (WHtR), Tri-Ponderal Mass Index (TMI), Body Adiposity Index (BAI), Body Shape Index (ABSI), Body Roundness Index (BRI), Abdominal Volume Index (AVI), and Conicity Index (CI) were calculated. The percentage of body fat (PBF) was measured with BIA. Results: Our study included 133 subjects (48.1% male, 77.4% pubertal) with a median age of 14.0 years (11.3 - 16.5) and a median duration of T1D of 4.5 years (1.5 - 7.3). The prevalence of overweight/obesity was 21.8% according to BMI-SDS and 30.1% according to BIA. BMI-SDS, WC, WHtR, TMI, AVI, BRI, and BAI were effective methods in differentiating overweight/obesity. BMI-SDS demonstrated a sensitivity of 78.79%, a positive predictive value of 72.22%, a negative predictive value of 89.71%, and an AUC of 0.895 at a cut point of 0.63, highlighting its effectiveness in distinguishing overweight/obesity. Conclusions: In children and adolescents with T1D, the prevalence of obesity/overweight identified using BIA was significantly higher compared to BMI-SDS. When reference methods are unavailable, BMI-SDS is the optimal anthropometric method for determining overweight/obesity in this population, independent of sex and puberty. These findings suggest that BMI-SDS can be a reliable alternative for body composition assessment, ensuring accurate identification and management of overweight/obesity in this population.


  • Open Access

    Adherence to Growth Hormone Treatment in Children During COVID-19 Pandemic

    by Erdal Eren, Semra Çetinkaya, Yasemin Denkboy Ongen, Ummahan Tercan, Şükran Darcan, Hande Turan, Fatma Yavuzyılmaz, Fatih Kilci, Beray Selver Eklioğlu, Nihal Hatipoğlu, et al.

    Objective: Treatment adherence is crucial for the success of growth hormone (GH) therapy. Reported non-adherence rates in GH treatment have varied widely. Several factors may have an impact on adherence. Apart from these factors, the global impact of the Coronavirus disease-2019 (COVID-19) pandemic, including problems with hospital admission and routine follow-up of patients using GH treatment, may have additionally affected the adherence rate. The primary objective of this study was to investigate adherence to treatment in patients receiving GH. In addition, potential problems with GH treatment during the pandemic were investigated. Methods: This was a multicenter survey study that was sent to pediatric endocrinologists during the pandemic period (June-December 2021). Patient data, diagnosis, history of pituitary surgery, current GH doses, duration of GH therapy, the person administering therapy (either parent/patient), duration of missed doses, reasons for missed doses, as well as problems associated with GH therapy, missed dose data and the causes in the recent year (after the onset of the pandemic) were questioned. Treatment adherence was categorized based on missed dose rates over the past month (0 to 5%, full adherence; 5.1 to 10% moderate adherence; >10% non-adherence). Results: The study cohort consisted of 427 cases (56.2% male) from thirteen centers. Median age of diagnosis was 8.13 (0.13-16) years. Treatment indications were isolated GH deficiency (61.4%), multiple pituitary hormone deficiency (14%), Turner syndrome (7.5%), idiopathic GH deficiency (7.5%), small for gestational age (2.8%), and "others" (6.8%). GH therapy was administered by parents in 70% and by patients in 30%. Mean daily dose was 32.3 big/kg, the annual growth rate was 1.15 standard deviation score (minimum-2.74, maximum 9.3). Overall GH adherence rate was good in 70.3%, moderate in 14.7%, and poor in 15% of the patients. The reasons for non-adherence were mainly due to forgetfulness, being tired, inability to access medication, and/or pen problems. It was noteworthy that there was a negative effect on adherence during the COVID-19 pandemic reported by 22% of patients and the main reasons given were problems obtaining an appointment, taking the medication, and anxiety about going to hospital. There was no difference between genders in the adherence rate. Non-adherence to GH treatment decreased significantly when the patient: administered the treatment; was older; had longer duration of treatment; and during the pandemic. There was a non-significant decrease in annual growth rate as non-adherence rate increased. Conclusion: During the COVID-19 pandemic, the poor adherence rate was 15%, and duration of GH therapy and older age were important factors. There was a negative effect on adherence during the pandemic period.


  • Open Access

    Acute Kidney Injury After Thyroid Hormone Withdrawal in an Adolescent with Papillary Thyroid Carcinoma

    by Yavuz Özer, RüvEyda GülMez, Hande Turan, GürKan Tarçın, Dilek Bingöl Aydın, Olcay Evliyaoğlu, Oya Ercan

    We report a patient with papillary thyroid carcinoma (PTC) who developed acute kidney injury (AKI) and elevated creatine kinase (CK) after thyroid hormone withdrawal (THW) prior to radioiodine therapy. A 12-year-old female patient who had undergone total thyroidectomy for PTC one year ago presented with leg pain for the past 2 days. Following THW 3 weeks ago, the case had received 70 mCI radioiodine treatment 6 days ago. Serum creatinine (1.53 mg/dL, normal range [NR]: 0.3-1.1), aspartate aminotransferase (102 IU/L, NR: 0-40) and CK (3451 IU/L, NR: 26-174) levels were elevated. Thyrotropin level was elevated (>100 µIU/ml, NR: 0.51-4.3), and free T4 level was decreased (0.05 ng/dL, NR: 0.98-1.63). Serum creatinine and CK levels decreased after intravenous hydration and levothyroxine treatment. In PTC cases with thyroidectomy, kidney function and CK elevation should be assessed after THW and dehydration should be prevented.

  • Open Access

    The effect of anastrozole therapy on final height and sex hormone levels in pubertal boys receiving growth hormone therapy

    by Gürkan Tarçın, Cansu Koç, Hande Turan, Oya Ercan

    Objective: This research aimed to evaluate retrospectively the effect of anastrozole on height gain and sex hormone levels in pubertal boys receiving growth hormone (GH). Materials and methods: Pubertal boys who received both GH and anastrozole (GH+A) were one-to-one matched with boys who received only GH (GH-Only) for chronological and bone age, pubertal stage and height before the GH initiation, treatment duration and midparental height. Anthropometric measurements throughout treatment and adult heights were compared between the groups. Sex hormone [...] ABSTRACT Objective: This research aimed to evaluate retrospectively the effect of anastrozole on height gain and sex hormone levels in pubertal boys receiving growth hormone (GH). Materials and methods: Pubertal boys who received both GH and anastrozole (GH+A) were one-to-one matched with boys who received only GH (GH-Only) for chronological and bone age, pubertal stage and height before the GH initiation, treatment duration and midparental height. Anthropometric measurements throughout treatment and adult heights were compared between the groups. Sex hormone


  • Open Access

    Temporary Thyroid Dysfunction and Catecholamine Excess Due to Mercury Poisoning in 6 Cases

    by Yavuz Özer, Mehmet Yıldız, Hande Turan, Aydilek Dağdeviren Çakır, Gürkan Tarçın, Dilek Bingöl Aydın, Elvan Bayramoğlu, Fatih Haşlak, Sezgin Şahin, Amra Adrovic, et al.

    Objective: Mercury poisoning is a condition with multiple-organ dysfunction that has effects on the central nervous system, gastrointestinal system, cardiovascular system, skin, lungs, and kidneys. It can be fatal or may result in sequelae such as neurological disturbances, if treated late or left untreated. The endocrinological effects of mercury exposure are not well-known. We aimed to evaluate patients with mercury poisoning. Materials and Methods: A total of 6 cases of mercury poisoning from 3 families were included in the study. Clinical, laboratory, and follow-up data were recorded. Results: Thyroid dysfunction was presented as high thyroid hormones and normal thyrotropin level (unsuppressed) in 5 cases (83.3%). On the other hand, pheochromocytoma-like syndrome was detected in 5 cases (83.3%) with hypertension. The 4 cases were the first to use methimazole for mercury poisoning due to tachycardia and hypertension despite antihypertensive treatment due to catecholamine excess and thyroid dysfunction. Hyponatremia was detected in 3 cases (50%). Conclusion: Mercury poisoning is difficult to diagnose because it is rare and presents with nonspecific physical and laboratory findings. Early diagnosis and providing appropriate treatment are essential in order to prevent sequelae. Mercury poisoning should be considered in patients with unexplained hypertension and tachycardia suggesting the involvement of thyroid hormones and catecholamines Cite this article as: Özer Y, Yıldız M, Turan H, et al. Temporary thyroid dysfunction and catecholamine excess due to mercury poisoning in 6 cases. Turk Arch Pediatr. 2024;59(1):23-30.